drugset
drugset / Trial / NCT06103695

Vtama in Psoriasis Patients Being Treated With Biologics.

NCT06103695 ↗

Phase 4 Completed 30 enrolled Psoriasis Treatment Center of Central New Jersey
NaSingle-groupOpen-labelTreatment

Summary

Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.

Timeline

Start
2023-02-27
Primary completion
2023-10-18
Completion
2023-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Tapinarof Other / unclassified — —

Indications

psoriasis